In regard to the activating roles of CARM1 toward p300/CBP, the Santos Lab recently described a synthetic lethality between the dual loss of CBP/p300 HAT and CARM1 methyltransferase activity in the context of diffuse large B cell lymphoma (DLBCL) (64). The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.